Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT).

Xavier RosselloSergio Raposeiras-RoubinRoberto LatiniAlberto Dominguez-RodriguezJosé A BarrabésPedro L SánchezManuel AnguitaFelipe Fernández-VázquezDomingo Pascual-FigalJosé M De la Torre HernandezStefano FerraroAlfredo VetranoJosé A Pérez-RiveraOscar Prada-DelgadoNoemí EscaleraLidia StaszewskyGonzalo PizarroJaume AgüeroStuart J PocockFilippo OttaniValentín FusterFrancesco Lavarranull null

Published in: European heart journal. Cardiovascular pharmacotherapy (2021)

The REBOOT trial will provide robust evidence to guide the prescription of β-blockers to patients discharged after MI without reduced LVEF.

Keyphrases

clinical trial
study protocol
end stage renal disease
ejection fraction
phase ii
newly diagnosed
chronic kidney disease
phase iii
angiotensin converting enzyme
open label
randomized controlled trial
double blind